PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL



Status:Recruiting
Conditions:Lung Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Lymphoma, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/26/2018
Start Date:June 15, 2018
End Date:December 2022
Contact:Annie Weaver, PhD
Email:clinicaltrials@cytomx.com
Phone:650-515-3185

Use our guide to learn which trials are right for you!

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

The purpose of this first-in-human study of CX-2029 is to characterize the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029
in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse
large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical
trial 001

PROBODY is a trademark of CytomX Therapeutics, Inc


Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced
unresectable tumors

2. Patients demonstrating disease progression after treatment with approved therapies
that are known to confer life-prolonging benefit, or who are intolerant to or have
declined treatment

3. Agreement to provide mandatory archival tissue or fresh biopsy

4. At least 18 years of age

Exclusion Criteria:

1. Neuropathy > Grade 1

2. Serious concurrent illness, including clinically relevant active infection

3. Clinically significant iron metabolism disorders (eg, sickle cell anemia)

4. Significant cardiac disease such as recent myocardial infarction

5. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome
(para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last
6 months, or alcoholic liver disease;

6. Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the
underlying neoplasm;

7. History of severe allergic or anaphylactic reactions to previous monoclonal antibody
therapy;

8. Currently receiving anticoagulation therapy with warfarin;

9. Major surgery (requiring general anesthesia) within 3 months prior to dosing.

10. Hepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C)

11. Transfusion dependent anemia with transfusion dependency of ≥3 months

12. Use of iron chelators
We found this trial at
5
sites
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials